All News

Image representing medical guidance

In this analysis, evidence was reviewed for the effectiveness of intranasal corticosteroids, biologics, and aspirin therapy after desensitization use among patients who have chronic rhinosinusitis with nasal polyposis (CRSwNP).

FDA Approves Efanesoctocog Alfa for Hemophilia A

Efanesoctocog alfa is the first factor VIII therapy to overcome the interaction with endogenous von Willebrand factor, which creates a ceiling of 8 to 19 hours on the half-life of current factor VIII replacement products, which in turn creates the need for more frequent dosing.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo